Toxicities of Novel Agents for the Treatment of Advanced Bladder Cancer
Enfortumab vedotin and erdafitinib have specific toxicities that need careful management in order to optimise drug exposure while maintaining patients’ quality of life. Patient education, meticulous monitoring, and a multidisciplinary approach are key to optimising outcomes so that patients can reap...
Saved in:
Published in | European urology focus Vol. 10; no. 2; pp. 222 - 223 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
01.03.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Enfortumab vedotin and erdafitinib have specific toxicities that need careful management in order to optimise drug exposure while maintaining patients’ quality of life. Patient education, meticulous monitoring, and a multidisciplinary approach are key to optimising outcomes so that patients can reap the benefits of these new treatments. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 2405-4569 2405-4569 |
DOI: | 10.1016/j.euf.2024.05.012 |